Cipla Q4: Why shares jumped 8% on May 14, 2026

Stock leads Nifty despite a weak quarter

Cipla shares jumped more than 8% on Thursday, May 14, 2026, to emerge as the top gainer on the Nifty 50, even though the company reported a sharp year-on-year drop in March-quarter profit. On the NIFTY 50, the stock rose as much as 8.62% to an intraday high of ₹1,442. Other reports placed the intraday high near ₹1,432-₹1,432.35 on NSE/BSE during the session.

The stock opened gap-up by 2.61% and extended gains through the day. It has now risen for two straight sessions, gaining about 11% over the two-day period after the results were announced during market hours on Wednesday. In the broader context, the rally also marked a recovery of about 23% from the 52-week low of ₹1,165.55 touched on April 2, 2026. Cipla’s 52-week high stood at ₹1,672.20, recorded on October 23, 2025.

What the March quarter numbers showed

Cipla reported a steep decline in consolidated profitability for Q4 FY26. Consolidated net profit fell 55.32% to ₹542.51 crore in the March quarter, compared with ₹1,214.14 crore in the same period last year. Another data point cited a roughly similar profit figure around ₹554-₹555 crore, versus about ₹1,222 crore last year.

Revenue also softened. Revenue from operations stood at ₹6,541.2 crore, down from ₹6,729.69 crore a year earlier, a decline of about 2.8%-3% year-on-year. The company attributed the earnings pressure to lower revenue from North America and higher expenses. Additional factors mentioned in reports included the absence of high-margin products such as Lenalidomide and Lanreotide, higher R&D investments, higher operating costs linked to scaling up US manufacturing facilities, and initial impact from geopolitical disruptions in West Asia.

North America dragged, while India delivered growth

The North America business was a key weak spot in the quarter. North America sales fell 26% to ₹1,414 crore, from ₹1,919 crore in the corresponding quarter last year.

At the same time, the “One India” business helped cushion the slowdown. One India sales rose 15% to ₹3,007 crore, from ₹2,622 crore a year ago. Management commentary highlighted that the India business is projected to see double-digit year-on-year growth in revenue and that this momentum is expected to sustain in FY27.

Margins and operating performance: EBITDA fell sharply

Operating profitability also contracted materially in Q4 FY26. One report said EBITDA fell 35% to ₹997 crore from ₹1,538 crore a year ago, with EBITDA margin contracting to 15.2% from 22.8%. Another cited EBITDA down 38% to ₹955 crore from ₹1,537.6 crore, with margin slipping to 14.6% from 22.8%.

Broker commentary, however, flagged some positives inside the numbers, including gross margin expansion quarter-on-quarter and a gross margin beat despite the EBITDA margin miss.

Brokerages focus on pipeline and earnings visibility

The rally was driven less by the reported Q4 profit drop and more by the “what next” narrative, especially around India growth, US launches, and the medium-term pipeline. Citigroup maintained a buy rating and raised its target price to ₹1,700. Citi described fourth quarter trends as steady, pointing to about 15% growth in India and US sales of $155 million, broadly stable sequentially despite phase-outs. It also pointed to gross margin expansion on a quarter-on-quarter basis and said management’s commentary on India growth, US sales outlook, and pipeline visibility remained positive.

JPMorgan upgraded Cipla to overweight with a target price of ₹1,550. The brokerage cited improved earnings visibility driven by complex US launches over the next two years and attractive valuations after the recent correction.

Other brokerage actions reported included Nuvama upgrading its rating to ‘Buy’ from ‘Reduce’ and raising its target price to ₹1,550. Emkay upgraded the stock to ‘Add’ from ‘Reduce’ and increased its target to ₹1,450, citing limited downside risk. HSBC maintained a hold rating with a target price of ₹1,340. Goldman Sachs maintained a neutral rating and raised its target price to ₹1,350, while Morgan Stanley maintained an underweight rating. Nirmal Bang was reported to have downgraded the stock to ‘Hold’ from ‘Buy’. JM Financial set a target price of ₹1,546 and upgraded the stock to BUY from ADD, citing improving visibility on US product launches.

Management’s FY27 cues: US ambition and run-rate commentary

Management’s forward commentary was a key support for sentiment. Cipla said it aspires to achieve $1 billion revenue from the US in FY27. Another reported management expectation that the US sales run-rate could improve to $150 million per quarter by the end of FY27, from $155 million in Q4 FY26 (excluding any Lanreotide revival).

The outlook also highlighted upcoming respiratory launches such as gSymbicort and gAdvair, and a broader pipeline spanning respiratory and peptides. Separately, ICICI Securities noted Cipla’s focus on biosimilars, with an ambition to add one to two in-house assets annually, building a pipeline of six to eight assets over five to eight years.

FY26 snapshot and dividend announcement

For the full year ended March 31, 2026, Cipla reported revenue of ₹28,163 crore, up 2% year-on-year, and net profit of ₹3,879 crore, down 26% year-on-year.

Alongside the Q4 results, the board recommended a final dividend of ₹13 per share for FY26. The record date to determine eligible shareholders was fixed as June 5.

Key figures at a glance

Market impact: what investors appeared to reward

The price action suggests investors are placing greater weight on forward indicators than the Q4 headline profit decline. The combination of double-digit India growth, planned complex US launches, and management’s stated US ambition helped shift focus toward FY27 and beyond. At the same time, the weak North America quarter and compressed EBITDA margins underline that the near-term earnings base remains under pressure.

Valuation and “visibility” were recurring themes in brokerage notes. Multiple firms pointed to improved earnings visibility over the next two years, while also flagging near-term headwinds from phase-outs and the earlier contribution of high-margin products. That mix, rather than a single quarter outcome, is what drove the divergence between the earnings print and the stock’s immediate reaction.

Conclusion

Cipla’s May 14 rally came even as Q4 FY26 profit and margins fell sharply year-on-year, with North America weakness a key drag. Still, brokerages broadly leaned constructive, focusing on India’s growth trajectory, planned complex US launches, and management’s FY27 commentary. The next key watchpoints include execution on the US pipeline, progress in restoring or replacing lost high-margin contributions, and the June 5 record date for the announced ₹13 final dividend.